A heterogeneous group of bone marrow (BM) failure disorders, myelodysplastic syndromes (MDS) is common in older adults. Sustained unilineage or multilineage cytopenia is included in the mandatory diagnostic criteria of MDS ([@A16]). Anemia and transfusion dependence are inevitable in the majority of patients, and hematologic improvement (HI) and transfusion independence (TI) remain primary endpoints of clinical trials incorporating disease-modifying therapies (DMTs). It is important to note that achieving HI and TI may require up to 4 months of consistent DMT. Thrombocytopenia and neutropenia, the most common adverse events (AEs) associated with DMT, are prevalent in the first 8 to 12 weeks of treatment. Thus, strategies to monitor and manage cytopenias in patients with MDS are critical to patient safety and to enable adequate duration of therapy to evaluate efficacy.
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Currently three DMTs are approved by the US Food and Drug Administration (FDA) for treatment of MDS, including two hypomethylating agents, azacitidine and decitabine, and the immunomodulatory agent, lenalidomide (Revlimid). The only oral DMT available for the treatment of MDS is lenalidomide. The currently FDA-approved starting dose for lenalidomide in patients with del(5q) MDS is 10 mg. This article focuses on the monitoring and management of lenalidomide-associated cytopenias expected in patients with MDS with del(5q).

LENALIDOMIDE IN THE TREATMENT OF MDS
====================================

Lenalidomide is an oral immunomodulatory drug that is licensed in the United States for patients with transfusion-dependent anemia due to International Prognostic Scoring System (IPSS) Low- or Intermediate-1 (Int-1)--risk MDS with del(5q) with or without additional cytogenetic abnormalities. In Europe, lenalidomide is licensed by the European Medicines Agency ([@A3]) for the treatment of patients with transfusion-dependent anemia due to Low- or Int-1--risk MDS associated with del(5q) when other therapeutic options are insufficient or inadequate.

Although lenalidomide is associated with achievement of durable red blood cell (RBC)-TI in patients in the MDS-003 and MDS-004 trials ([@A5]; [@A11]), the most common AEs associated with lenalidomide treatment are neutropenia and thrombocytopenia. Familiarity with the incidence and time to onset of lenalidomide-related cytopenias, together with strategies for management, may help to realize the maximum potential benefit of therapy.

STUDY DETAILS FROM MDS-003 AND MDS-004
======================================

Data from MDS-003 and MDS-004, and real-world patient experience, were used in summarizing the incidence of expected lenalidomide-associated cytopenias and in outlining strategies for practical management of cytopenias in patients with MDS. MDS-003 was a phase II, multicenter, single-arm study of 148 patients with lower-risk MDS (LR-MDS) and del(5q; [@A11]). Patients received 10 mg of lenalidomide daily for 21 days in 28-day cycles (n = 46) or as a 10-mg continuous daily dose (n = 102). MDS-004 was a phase III, multicenter, randomized, placebo-controlled, double-blind study of 138 patients with LR-MDS and del(5q; [@A5]). Patients were randomized to receive 10 mg of lenalidomide daily for 21 days in 28-day cycles (n = 69), a 5-mg continuous daily dose (n = 69), or a continuous daily dose of placebo (n = 67).

The incidence, time to onset, and recovery from cytopenias, as well as the incidence of lenalidomide dose modifications and discontinuations due to neutropenia or thrombocytopenia, were examined in patients from MDS-003 and MDS-004. Data were compared with long-term outcomes in the Case Study patient with LR-MDS and del(5q) who participated in the dose-finding MDS-001 trial ([@A12]). These data and expert experience were used to develop a practical approach to the management of cytopenias in lenalidomide-treated patients with MDS with del(5q).

EXPECTED CYTOPENIAS: DATA FROM MDS-003 AND MDS-004
==================================================

The most common grade ≥ 3 AEs in 286 patients treated with lenalidomide in the MDS-003 and MDS-004 trials were neutropenia (64%) and thrombocytopenia (41%; [@A5]; [@A11]). Grade ≥ 3 neutropenia and thrombocytopenia occurred most frequently during the first two treatment cycles ([@A5]; [@A6]; [@A11]). In MDS-003, 62% of grade ≥ 3 hematologic AEs occurred in the first two treatment cycles ([@A11]). The median time to onset of grade ≥ 3 neutropenia in the study was 42 days (range, 14--411 days), and the documented median time to recovery was 17 days (range, 2--170 days; [@A1]). The median time to onset of thrombocytopenia was 28 days (range, 9--290 days), and the documented median time to recovery was 22 days (range, 5--224 days; [@A1]). It is important to note that patients with severe neutropenia (\< 500 polymorphonuclear neutrophils/mm³) or severe thrombocytopenia (platelet count \< 50,000/mm³) were excluded from MDS-003 ([@A11]), and patients with abnormal blood cell counts, including those with an absolute neutrophil count \< 500/∝L or a platelet count \< 25,000/∝L, were excluded from MDS-004 ([@A5]).

In both trials, cytopenias were managed according to trial protocols, with dose interruptions of up to 21 days until cytopenias resolved to grade ≤ 2 and subsequent dose reductions when treatment was reinitiated. Thrombocytopenia and neutropenia were the most common reasons for lenalidomide dose modifications ([Table 1](#T1){ref-type="fig"}; [@A5]; [@A11]). Treatment discontinuations due to neutropenia or thrombocytopenia in MDS-004 were infrequent relative to the incidence of these AEs, which suggests management with dose interruption and subsequent dose reduction is effective ([@A5]).

![Action Taken in Response to Lenalidomide-Associated Grade ≥ 3 Cytopenias in MDS-003 and MDS-004](jadp-08-721-g02){#T1}

In MDS-003 and MDS-004, use of myeloid growth factors (MGF) was permitted for the management of neutropenia ([@A5]; [@A12], [@A11]). Routine use of MGF to prevent infection is not recommended for patients with MDS ([@A13]), however, for patients with active infections or neutropenic fever, MGF, granulocyte colony-stimulating factors filgrastim (Neupogen) and pegfilgrastim (Neulasta), can be safely administered to patients concurrently with lenalidomide and might limit the severity of infections and the need for repeated dose reductions of lenalidomide ([@A8]).

In MDS-003, three deaths were attributed to neutropenic infection, which demonstrates the importance of closely monitoring patients for AEs and the potential role of MGF and other supportive care measures to alleviate neutropenia and infections ([@A11]). In MDS-004, 39 patients (57%) who received 10 mg of lenalidomide and 38 patients (55%) who received 5 mg of lenalidomide were given MGF ([@A5]). There were no deaths due to neutropenic infection, which may be the result of better monitoring and management of neutropenia. Concurrent use of MGF to treat neutropenia had no significant effect on the response to lenalidomide ([@A5]).

In MDS-003, treatment-emergent thrombocytopenia in patients with del(5q) MDS on lenalidomide was associated with an increased probability of achieving RBC-TI ([@A14]). By contrast, thrombocytopenia at baseline was associated with a low probability of patients achieving RBC-TI. Patients with baseline thrombocytopenia had significantly fewer consecutive days of lenalidomide treatment than those with treatment-emergent thrombocytopenia, as dose interruptions were required to manage thrombocytopenia ([@A11]). In patients with baseline thrombocytopenia, low exposure to lenalidomide may reduce the probability of an erythroid response. In addition, patients with a normal platelet count at the start of treatment who develop thrombocytopenia may go on to have a favorable erythroid response, emphasizing the importance of effective management strategies and continued treatment.

The mean time to response in patients with MDS and del(5q) treated with lenalidomide was variable. In MDS-003, the median time to RBC-TI was 4.6 weeks (range, 1--49 weeks; [@A11]). In MDS-004, the onset of an erythroid response occurred in 48.8% of patients during cycle 1, 37.2% of patients during cycle 2, 9.3% of patients during cycle 3, and 4.7% of patients during cycle 4 ([@A5]). This variation in the time to response emphasizes the need for an adequate trial length (minimum of 4 months) to achieve maximal benefit in the absence of intolerance or unacceptable drug toxicity. Early discontinuation of treatment, unfortunately, remains common, essentially exposing patients to drug toxicity without the full potential for benefit ([@A7]). Continuation of therapy until unacceptable toxicity or disease progression is recommended in patients who respond to lenalidomide ([@A1]; [@A5]; [@A11]).

PRACTICAL GUIDANCE FOR MANAGEMENT OF CYTOPENIAS
===============================================

Perhaps the most important factor to ensure an adequate clinical trial of lenalidomide is to set expectations that 4 months of treatment are needed to adequately evaluate response. Establishment of expectations at the outset of treatment, together with a formal plan to monitor blood cell counts and tolerance, is essential to maintain treatment in the first 12 weeks. This level of care requires a partnership between the health-care provider (HCP), the patient, and the patient's caregivers.

Weekly blood cell counts are necessary in the first 8 weeks. The results must be reviewed and acted upon to improve early recognition of cytopenias, enable prompt management, and minimize the severity of complications. Patients treated with lenalidomide should be educated about the signs and symptoms that warrant making contact with an HCP, including who to call and when. The recommended management of lenalidomide-related neutropenia and thrombocytopenia is available in the lenalidomide package insert ([@A1]). Advice is given on dose interruptions and dose reductions dependent upon criteria such as the initial lenalidomide dose, severity, and time of onset of cytopenias.

Summaries of the guidelines for the management of cytopenias within the first 4 weeks and after 4 weeks of lenalidomide treatment are shown in Tables [2](#T2){ref-type="fig"} and [3](#T3){ref-type="fig"}, respectively. Guidelines may need to be tailored to individual patients based on their BM reserve, proximity to the treatment center, and availability of transfusion services and emergency care services ([@A9]). Additional tips for management of cytopenias in this patient population, gleaned from trial reports and clinical experience, are summarized in [Table 4](#T4){ref-type="fig"}.
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Adverse events (bacteremia and mucositis) seen in patients with cytopenias and acute myeloid leukemia are much less common in patients with Low-/Int-1--risk MDS and in many patients with Int-2--risk MDS receiving DMTs ([@A7]). It is also important to remember that several commonly used medications, including some over-the-counter medications, can cause cytopenias. Caution is therefore warranted when patients use these agents concomitantly with lenalidomide. Examples of common medications that can exacerbate thrombocytopenia include anti-inflammatory drugs (e.g., aspirin, ibuprofen, naproxen, acetaminophen), antimicrobial agents (cephalosporins, penicillins), and anticoagulants (warfarin, dalteparin \[Fragmin\], rivaroxaban \[Xarelto\]; [@A17]).

DISCUSSION
==========

Most responses to lenalidomide occur rapidly after treatment initiation; however, it may take up to four treatment cycles (16 weeks) to achieve HI and RBC-TI ([@A5]). At least four cycles of treatment with lenalidomide are recommended in patients with del(5q) MDS to adequately evaluate response ([@A8]; [@A12]). Cytopenias, specifically neutropenia and thrombocytopenia, are the most common AEs reported in patients with LR-MDS and del(5q) receiving lenalidomide ([@A1]; [@A4], [@A5]; [@A11]) and are the most common in the first 8 weeks of treatment. Blood counts, therefore, should be monitored weekly during this period to mitigate risks and institute the recommended dose modifications and supportive care strategies. Continuation of therapy until unacceptable toxicity or disease progression based on the International Working Group criteria ([@A2]) is recommended for patients who achieve HI or TI.

Sustained, moderate, but asymptomatic cytopenias are common in patients being treated with lenalidomide and other DMTs for MDS ([@A8]; [@A10]). In the absence of acute symptoms (e.g., fever, chills, active infection, bleeding), moderate cytopenias do not require dose reduction or discontinuation of therapy. Most patients who develop symptomatic or more severe cytopenias can be effectively managed with dose modifications and supportive care, which avoids premature discontinuation of therapy and improves the potential to achieve maximum benefit ([@A1]; [@A4], [@A5]; [@A9]; [@A11]). Our case study of a patient who received lenalidomide for 11 years with sustained RBC-TI illustrates how moderate but asymptomatic neutropenia and thrombocytopenia do not require dose interruptions and may be managed without the need for continued lenalidomide dose modifications or discontinuation.

Currently only three FDA-approved agents are available for the treatment of MDS; as two of these agents are similar drugs, it is imperative to maximize the use of each one. Establishment of expectations, organization of a plan for weekly laboratory tests with a review of results and follow-up visits, and utilization of dose interruptions and reductions in the early weeks of treatment provide practical strategies to manage cytopenias in patients receiving lenalidomide for del(5q) MDS that will enable them to continue therapy and achieve optimal clinical benefit.
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